Unique mode of action
The therapeutic target is cPLA₂α, a key enzyme that causes release of arachidonic acid, which in turn activates multiple inflammatory and proliferative processes that play a fundamental role in many diseases. Selective inhibition of cPLA₂α with Coegin's drug candidates blocks this mechanism and reduces inflammation and cell proliferation.
Coegin Pharma's main objective is to develop a better treatment option for cancerous and pre-cancerous indications such as actinic keratosis. We are building value by means of a strong pipeline in both skin cancer and systemic treatment of cancer, where the focus is on leukemia and breast cancer. We have seen very promising pre-clinical results in both fibrosis and chronic kidney disease, which we are planning to pursue further.
Business model and strategy
Coegin Pharma's business model is based on efficient development of new, innovative drug candidates for diseases with an urgent medical need, where the key enzyme cPLA₂α is central to the disease progression. The company advances development of active drug candidates from discovery to either Phase IIa or Phase IIb, with the intention of subsequent out-licensing to international partners.
The interesting thing about Coegin Pharma is the unique therapeutic platform based on decades of successful research into the clinically well-validated target enzyme cPLA₂α, which plays a key role in many diseases associated with cancer, inflammation and fibrosis. We are building value by means of a strong pipeline in both skin cancer and systemic treatment of cancer, where the focus is on leukemia and breast cancer. We have seen very promising pre-clinical results in both fibrosis and chronic kidney disease, which we are planning to pursue further.
Actinic keratosis is a very common disease that risks developing into a serious form of skin cancer, where the available treatment is often time-consuming and insufficient. The clinical trial in actinic keratosis is innovative and patient-centric. Digitalization allows the study to be conducted smarter, faster, and with better use of clinical data. We have already started preparations to conduct a new Phase IIa clinical trial in skin cancer in 2022, more specifically in basal cell carcinoma.